Adding below Omkar IR’s response to few questions that I had asked them over the e-mail.

1. Finance Costs –
   1. I heard in the concall that the short term debt has been converted into long term debt. E.g. given was of a 1 year loan getting converted into a 2 year loan. What is the purpose of re-structuring debt like this?
      Ans.- Since, the STL were putting pressure on cash flow, hence, some of the Short Term debts have been renegotiated with lenders and converted as Long Term debts.

 2. The above restructuring i.e. converting short term debt into long term I assume should result in interests costs going down. But I see that the finance costs have been going up. What is the reason for finance costs going up despite a re-structuring like above? 
 Ans.- The conversion was done at the end of quarter hence there is no significant change in interest cost. The additional finance cost is due to interest on Loan against shares.

 3. Has any extra debt been taken? And, if yes then for what purpose? 
 Ans.- Rs.4 crore additional limits were sanctioned by Bank to meet the additional working capital requirement of Lasa.Has our company being capitalizing interests costs? If yes, then why? No interest capitalization during the quarter.

1. Process Patents-
   1. Assuming that these process patents result in reducing costs, what is the impact of these process patents on costs i.e. by what percentage are the costs brought down?
      Ans.- Around 15%.

 2. If possible can the impact of these process patents on Margins be stated? 
 Ans.- The impact of these process patent can be seen in the long run.

 3. What were the savings in H1 FY16 and Q2 FY16 because of these process patents? 
 Ans.- Direct saving cant be quantified but Increase in sales revenue, Having good concrete order book in Hand are the Advantages and results of Having Process patents.

 4. Do these process patent provide any competitive advantages over competitors? 
 Ans.- Yes.

 5. Don't competitors come up with such process patents? 
 Ans.- So far the competitors have not developed such processes.

1. Raw Materials-
   1. What is the outlook going ahead on raw material prices?
      Ans.- We expect the raw material prices to remain stable in near future. As most of our RM are basic petro Chemicals.

 2. What is the percentage of imported raw material costs as a part of overall raw material costs and as a percentage of sales? 
 Ans.- Will be Provided shortly.

1. Does our company enter into any forward contracts to hedge currency fluctuations? If yes, then can you state the amount of such forward contracts as on date?
   Ans. No. Generally we have natural hedging on account of forex inflow on the export sales made by the company.

2. Are there any inspections and certifications lined up from regulated markets in Europe and USA for our plants? If yes, then from which markets and regulators? And till when will our plants receive those
   certifications or approvals?
   Ans.- Yes. We are planning approval of TGA as Our API has high demand in Australia and New Zealand(2-3 Months approx.). Also at later stage were are planning to Get US FDA as well. (Around a year’s time Max)

alembic q2 fy 16 results seem to be better than expected.

What is more encouraging is the amount of R&d spend.

Some good things coming out of results are:

Launch of own front end marketing in the US market

21% growth of speciality segment in the domestic markets. (this is considered as the big growth driver in domestic markets)

Market reactions can be well wide of our expectations in the short term. e.g One can see the torrent stock price after stupendous q1 fy 16 results. and after a few trading sessions it was business as usual.

With some guys I talked to after results, the big question is what would be normalised earnings in absence of abilify kind of revenues in fy 17. My take is that one can start off by calculating a calibrated growth from eps figures of 15 in fy 15 and put in a 25-35% growth depending upon one’s bullishness.

And with the kind of pipeline alembic has there can be a few other blockbuster opportuniites. And going ahead with its own marketing network, it can milk the opportunity if and when it comes fully.

Another thing they could do would be to sell some existing molecules thru its own marketing network and thus improve margins further.

disc: invested

Is Vinati Saraf Mutreja wife of Mohit Mutreja?
The both are board of directors. Mohit is founder and MD of another company Alphagrep securities (trading).

Couldn’t understand the price movement, post the result. I was hoping for an upper circuit kind of move, with these results but Mr.market gave Alembic a sulk. Can anyone weigh in here ? Is this considered a flash in the pan result ? After all, this isn’t like your Lupin result ( annus horribilis) announced today. Hoping for some insights